Outcome of Annual General Meeting of May 22, 2019
Marseille, France, May 23, 2019, 7:00 AM CEST
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces the results of the voting by shareholders at the Annual General Meeting (“AGM”) which took place on May 22, 2019, in Marseille, France. All resolutions were voted in accordance with the management team’s recommendations.
A total of 27,276,527 votes was cast out of a total of 64,039,842 shares with voting rights, representing a quorum of 42.593%.
Details of the votes are available on the Company’s website, in the Annual General Meeting 2019 section.
About Innate Pharma:
Innate Pharma S.A. is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.
Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia (HCL). Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.
Pioneer in the biology of NK cell, Innate Pharma has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.
Based in Marseille, France, Innate Pharma is listed on Euronext Paris.
Learn more about Innate Pharma at www.innate-pharma.com
Information about Innate Pharma shares:
ISIN code FR0010331421 Ticker code IPH LEI 9695002Y8420ZB8HJE29
This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma’s website.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
For additional information, please contact:
Investors International Media Innate Pharma Consilium Strategic Communications Dr. Markus Metzger/ Danielle Spangler Mary-Jane Elliott / Jessica Hodgson Jérôme Marino Tel.: +33 (0)4 30 30 30 30 Tel.: +44 (0)20 3709 5700 email@example.com InnatePharma@consilium-comms.com French Media ATCG Press Solène Moulin / Marie Puvieux Tel.: +33 (0)9 81 87 46 72 firstname.lastname@example.org
-- 190523 IPH_PR_AGM results